Elevated Platelet Galectin-3 and Rho-Associated Protein Kinase Activity Are Associated with Hemodialysis Arteriovenous Shunt Dysfunction among Subjects with Diabetes Mellitus

Autor: Jia Rong Yu, Ping Yen Liu, Ting Chun Huang, Ling Wei Hsu, Hsin Yu Liao, Hsien Yuan Chang, Cheng Han Lee, Po Wei Chen
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Blood Platelets
Male
0301 basic medicine
medicine.medical_specialty
Myosin Light Chains
RHOA
Article Subject
Galectin 3
Galectins
medicine.medical_treatment
lcsh:Medicine
030204 cardiovascular system & hematology
Gastroenterology
General Biochemistry
Genetics and Molecular Biology
Myosin-Light-Chain Phosphatase
03 medical and health sciences
Arteriovenous Shunt
Surgical
0302 clinical medicine
Renal Dialysis
Internal medicine
Diabetes mellitus
Diabetes Mellitus
Humans
Medicine
Platelet
Prospective Studies
Phosphorylation
Prospective cohort study
Rho-associated protein kinase
Aged
rho-Associated Kinases
General Immunology and Microbiology
biology
business.industry
lcsh:R
Blood Proteins
General Medicine
medicine.disease
Venous thrombosis
030104 developmental biology
Arteriovenous Fistula
biology.protein
Biomarker (medicine)
Female
Hemodialysis
rhoA GTP-Binding Protein
business
Signal Transduction
Research Article
Zdroj: BioMed Research International, Vol 2019 (2019)
BioMed Research International
ISSN: 2314-6141
2314-6133
Popis: Introduction. Hyperglycemia is a major factor in influencing the patency rate of arteriovenous shunts, potentially associated with the RhoA/Rho-associated protein kinase (ROCK) pathway. Besides, galectin-3 mediates thrombotic mechanisms in venous thrombosis and peripheral artery disease. We hypothesized that high ROCK activity and galectin-3 levels are associated with arteriovenous shunt dysfunction. Methods. We prospectively enrolled 38 patients diagnosed with arteriovenous shunt dysfunction. 29 patients received a complete follow-up and each provided two blood samples, which were collected at the first visit for occluded status of arteriovenous shunts and 1 month later for patent status. A Western blot assay for a myosin phosphatase target subunit (MYPT) was performed to examine Rho-kinase activity. A Western blot assay for platelet galectin-3 and enzyme-linked immunosorbent assay (ELISA) for circulating galectin-3 were completed. Results. Higher platelet MYPT ratios and galectin-3 levels were identified at occluded arteriovenous shunts (MYPT ratio: 0.5 [0.3–1.4] vs. 0.4 [0.3–0.6], p = 0.01; galectin-3: 1.2 [0.4–1.6] vs. 0.7 [0.1–1.2], p = 0.0004). The plasma galectin-3 binding protein ELISA was also higher at occluded arteriovenous shunts (8.4 [6.0–9.7] μg/mL vs. 7.1 [4.5–9.1] μg/mL, p = 0.009). Biomarker ratios (occluded/patent status) trended high in patients with poorly controlled diabetes (MYPT ratio: 1.7 [1.0–3.0] vs. 1.1 [0.7–1.3], p = 0.06; galectin-3: 1.6 [1.3–3.4] vs. 1.1 [0.8–1.9], p = 0.05). Conclusion. High platelet ROCK activity and galectin-3 levels are associated with increased risk in arteriovenous shunt dysfunction, especially in patients with poorly controlled diabetes.
Databáze: OpenAIRE
Externí odkaz: